Johnson & Johnson (NYSE:JNJ) Releases FY 2025 Earnings Guidance

Johnson & Johnson (NYSE:JNJ - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 10.800-10.900 for the period, compared to the consensus EPS estimate of 10.620. The company issued revenue guidance of $93.2 billion-$93.6 billion, compared to the consensus revenue estimate of $91.4 billion.

Analyst Ratings Changes

Several brokerages have issued reports on JNJ. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Raymond James Financial reduced their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. Finally, Bank of America reduced their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, April 10th. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $171.00.

Johnson & Johnson Stock Up 6.2%

NYSE JNJ traded up $9.61 on Wednesday, hitting $164.78. The stock had a trading volume of 22,128,650 shares, compared to its average volume of 8,149,674. The business's fifty day moving average price is $153.80 and its 200 day moving average price is $154.64. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The stock has a market cap of $396.47 billion, a price-to-earnings ratio of 18.33, a price-to-earnings-growth ratio of 2.14 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period in the previous year, the company earned $2.82 earnings per share. The business's revenue for the quarter was up 5.8% on a year-over-year basis. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.16%. Johnson & Johnson's payout ratio is currently 57.84%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Johnson & Johnson stock. Brighton Jones LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 51,876 shares of the company's stock after purchasing an additional 6,332 shares during the period. Brighton Jones LLC's holdings in Johnson & Johnson were worth $7,502,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.